CN106083976B - 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS) - Google Patents

用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS) Download PDF

Info

Publication number
CN106083976B
CN106083976B CN201610412359.9A CN201610412359A CN106083976B CN 106083976 B CN106083976 B CN 106083976B CN 201610412359 A CN201610412359 A CN 201610412359A CN 106083976 B CN106083976 B CN 106083976B
Authority
CN
China
Prior art keywords
compound
25hcds
disease
liver
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610412359.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106083976A (zh
Inventor
S·任
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of CN106083976A publication Critical patent/CN106083976A/zh
Application granted granted Critical
Publication of CN106083976B publication Critical patent/CN106083976B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201610412359.9A 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS) Expired - Fee Related CN106083976B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12
US61/623,203 2012-04-12
US61/623,414 2012-04-12
CN201380019476.3A CN104220450B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380019476.3A Division CN104220450B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Publications (2)

Publication Number Publication Date
CN106083976A CN106083976A (zh) 2016-11-09
CN106083976B true CN106083976B (zh) 2018-02-09

Family

ID=49328028

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610412359.9A Expired - Fee Related CN106083976B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
CN201380019476.3A Expired - Fee Related CN104220450B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380019476.3A Expired - Fee Related CN104220450B (zh) 2012-04-12 2013-03-15 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Country Status (20)

Country Link
US (6) US20150072962A1 (https=)
EP (2) EP3239163A1 (https=)
JP (4) JP6125610B2 (https=)
KR (1) KR102180485B1 (https=)
CN (2) CN106083976B (https=)
AU (2) AU2013246435B2 (https=)
BR (1) BR112014025081B1 (https=)
CA (1) CA2867694C (https=)
DK (1) DK2836502T3 (https=)
EA (1) EA026683B1 (https=)
ES (1) ES2641841T3 (https=)
HU (1) HUE035073T2 (https=)
IL (1) IL234892B (https=)
IN (1) IN2014KN02366A (https=)
MX (1) MX357046B (https=)
PL (1) PL2836502T3 (https=)
PT (1) PT2836502T (https=)
SI (1) SI2836502T1 (https=)
WO (1) WO2013154752A1 (https=)
ZA (1) ZA201406981B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EA026683B1 (ru) * 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА
PL3639828T3 (pl) * 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107106576A (zh) * 2014-10-10 2017-08-29 弗吉尼亚联邦大学 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类
JP6784963B2 (ja) * 2014-12-24 2020-11-18 国立大学法人京都大学 ビタミンｄ３誘導体及びその薬学的用途
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CA3031211A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
RU2020110253A (ru) * 2017-08-31 2021-09-30 Ариэль Сайентифик Инновейшнз Лтд Экстракт s. spinosum для лечения жировой болезни печени
BR112022005039A2 (pt) * 2019-09-30 2022-06-21 Durect Corp Tratamento de hepatite alcoólica
EP4171573A4 (en) * 2020-06-26 2025-04-09 Durect Corporation USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES AND ADDICTION
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR102732697B1 (ko) 2021-10-29 2024-11-25 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357003A (zh) * 1999-04-30 2002-07-03 亚其发展公司 类固醇衍生物
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CN104220450B (zh) * 2012-04-12 2016-07-06 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637884A1 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357003A (zh) * 1999-04-30 2002-07-03 亚其发展公司 类固醇衍生物
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CN104220450B (zh) * 2012-04-12 2016-07-06 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5-胆甾烯-3β,25-二醇二硫酸酯(25HCDS)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
24-Hydroxycholesterol Sulfation by Human Cytosolic Sulfotransferases: Formation of Monosulfates and Disulfates,Molecular Modeling, Sulfatase Sensitivity, and Inhibition of Liver X Receptor Activation;Ian T. Cook等;《DRUG METABOLISM AND DISPOSITION》;20091231;第37卷(第10期);第2069-2078页 *
25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway;Yongjie Ma等;《Am.J.Physiol.Endocrinol.Metab.》;20081014;第295卷(第6期);第1369-1379页 *
Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes;Shunlin Ren等;《Biochemical and Biophysical Research Communications》;20070907;第360卷(第4期);第802-808页 *
孕甾-5-烯23β, 20-二取代硫酸酯钠盐的合成;李莹等;《广西师范学院学报（自然科学版）》;20090630;第26卷(第2期);第52-54页 *

Also Published As

Publication number Publication date
BR112014025081A2 (pt) 2018-05-08
PT2836502T (pt) 2017-10-27
JP2015512937A (ja) 2015-04-30
ES2641841T3 (es) 2017-11-14
DK2836502T3 (en) 2017-10-23
ZA201406981B (en) 2016-05-25
KR102180485B1 (ko) 2020-11-18
AU2017268646B2 (en) 2019-07-11
JP6125610B2 (ja) 2017-05-10
EP3239163A1 (en) 2017-11-01
BR112014025081B1 (pt) 2020-12-08
CA2867694A1 (en) 2013-10-17
SI2836502T1 (sl) 2017-11-30
AU2013246435B2 (en) 2017-10-05
US20180127457A1 (en) 2018-05-10
PL2836502T3 (pl) 2018-01-31
EA201491859A1 (ru) 2015-02-27
US20150072962A1 (en) 2015-03-12
US20210238219A1 (en) 2021-08-05
JP2021138713A (ja) 2021-09-16
US20190135856A1 (en) 2019-05-09
WO2013154752A1 (en) 2013-10-17
US20160355544A1 (en) 2016-12-08
CA2867694C (en) 2021-08-31
EP2836502B1 (en) 2017-08-02
CN104220450A (zh) 2014-12-17
HK1202294A1 (en) 2015-09-25
US20200157140A1 (en) 2020-05-21
CN106083976A (zh) 2016-11-09
EP2836502A4 (en) 2015-08-19
HUE035073T2 (en) 2018-05-02
EP2836502A1 (en) 2015-02-18
IN2014KN02366A (https=) 2015-05-01
AU2017268646A1 (en) 2017-12-21
CN104220450B (zh) 2016-07-06
JP2017160213A (ja) 2017-09-14
MX2014012324A (es) 2015-05-11
AU2013246435A1 (en) 2014-10-16
EA026683B1 (ru) 2017-05-31
KR20150013520A (ko) 2015-02-05
JP2019089777A (ja) 2019-06-13
MX357046B (es) 2018-06-22
IL234892B (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CN106083976B (zh) 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
US10144759B2 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2020244454A1 (zh) 五环三萜皂苷化合物的医药用途及其药物组合物
US9884066B2 (en) Bile acid-basic amino acid conjugates and uses thereof
CN110437297A (zh) 法尼醇x受体的抑制剂和在医学中的用途
US20130143854A1 (en) Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US11447522B2 (en) Potent soft anti-inflammatory corticosteroid compounds and uses thereof
HK1202294B (en) A novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
WO1994013690A1 (en) New steroids
US20240316073A1 (en) Cannabidiolic acid esters for treating prader-willi syndrome
JP5201546B2 (ja) Ｎ‐アセチルシステイン抱合型胆汁酸、それを含有する医薬組成物及びその製造方法
CN115814093A (zh) 肠道菌aps还原酶抑制剂联合穿心莲内酯在治疗胆汁淤积性肝损伤中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180209